Samyang Biopharm announced that it participated in three major global academic events in the field of biopharmaceuticals and gene therapy held in Boston from May 11 to 15, where it showcased the capabilities and commercialization strategies of its next-generation drug delivery platform, SENS.
During the event, the company operated a partnering booth and meeting rooms, planning to explore collaboration opportunities with global pharmaceutical and biotech companies through oral and poster presentations.
The company first participated in 'TIDES USA 2026,' the world's largest international conference in the field of nucleic acid and peptide therapeutics, sharing its latest research findings and seeking collaboration opportunities. This year, over 500 global pharmaceutical and biotech companies from approximately 40 countries are participating.
At the event, Sunny Song, head of the New Drug Business Unit, will deliver an oral presentation revealing research results optimized for the SENS platform technology.
Specifically, to advance the development of next-generation drugs based on SENS, the company will present four key strategies: in vivo production of biopharmaceuticals, adaptive precision therapy, cell function modulation therapy, and targeted cell regulation, while discussing joint research and business development with global pharmaceutical and biotech firms.
Samyang Biopharm will also participate in the international conferences 'ASGCT 2026' and 'PEGS Boston Summit.' At ASGCT, the company will present research results on the Hepa-SENS platform for targeted delivery to liver cells and the potential of next-generation nucleic acid delivery technologies.
At the PEGS Boston Summit, the company aims to understand the latest research trends in protein and antibody engineering, immunotherapy, and next-generation biopharmaceuticals, while discussing collaboration with global experts focusing on active targeting technologies, targeted binding and intracellular delivery strategies, and analytical and characterization technologies.
SENS, developed by Samyang Biopharm, is a drug delivery platform designed to selectively deliver nucleic acid-based therapeutics, such as short interfering RNA (siRNA) and messenger RNA (mRNA), as well as gene-editing drugs to specific tissues and cells. It is characterized by its ability for repeated administration and high safety. The platform was awarded the 'Most Promising Cell and Gene Therapy Pipeline' at the 'Korea BioPharma Excellence Awards (KBEA) 2024.'
A representative from Samyang Biopharm stated, "We plan to expand global partnerships in the field of gene therapies and next-generation nucleic acid therapeutics. We expect that the completion of our gene therapy production facility, scheduled for the third quarter of next year, will accelerate the entry of our developing new drugs into clinical trials."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.